Payment overview · 2025
General Payments
$547.73
37 reported records · 11 companies
Healthcare provider profile · identity verified
David W Clay, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FAYETTEVILLE, AR · NPI 1093741910
Verified facts
What the public records show
CMS Open Payments records show David W Clay, MD received $547.73 in general payments during 2025 across 37 reported records.
PFIZER INC. accounted for 30.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROCYSBI as an associated drug or biological on 108 records involving 21 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Procysbi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $168.93 | 30.8% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $95.13 | 17.4% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $71.80 | 13.1% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $53.82 | 9.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.05 | 5.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.97 | 5.3% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $25.90 | 4.7% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.87 | 4.2% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $22.22 | 4.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.66 | 2.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.38 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $547.73 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $117.15 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $95.13 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $76.33 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $72.63 | 3 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $71.80 | 4 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $53.82 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $51.78 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $51.78 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $51.78 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $40.82 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.05 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.05 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.97 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.97 | 2 | 2025 |
Source payment records
|
|||||
| Kcentra Normalized: kcentra |
Biological | CSL Behring | $25.90 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $22.87 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 213 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
86 | 19 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROCYSBI open payments reported associated product |
CMS Open Payments — General Payments 108 supporting records · 21 recipient NPIs · example record 1226872879 |
Procysbi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
213 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 638 | 123 |
| Atorvastatin Calcium | Atorvastatin Calcium | 603 | 138 |
| Lisinopril | Lisinopril | 532 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 485 | 106 |
| Metformin Hcl | Metformin Hcl | 413 | 84 |
| Omeprazole | Omeprazole | 336 | 81 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 310 | 68 |
| Citalopram Hbr | Citalopram Hydrobromide | 273 | 52 |
| Clonazepam | Clonazepam | 249 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 229 | 51 |
| Gabapentin | Gabapentin | 224 | 49 |
| Eliquis | Apixaban | 213 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 205 | 45 |
| Losartan Potassium | Losartan Potassium | 203 | 54 |
| Valsartan | Valsartan | 199 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 49 |
| Furosemide | Furosemide | 197 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 37 |
| Potassium Chloride | Potassium Chloride | 158 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 44 |
| Simvastatin | Simvastatin | 144 | 36 |
| Trazodone Hcl | Trazodone Hcl | 140 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 35 |
| Tramadol Hcl | Tramadol Hcl | 138 | 35 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 138 | 32 |
| Xarelto | Rivaroxaban | 136 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 32 |
| Sertraline Hcl | Sertraline Hcl | 126 | 24 |
| Meloxicam | Meloxicam | 118 | 29 |
| Carvedilol | Carvedilol | 114 | 25 |
| Alprazolam | Alprazolam | 110 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 110 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 106 | 22 |
| Allopurinol | Allopurinol | 102 | 24 |
| Atenolol | Atenolol | 98 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 16 |
| Ezetimibe | Ezetimibe | 96 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 93 | 18 |
| Ozempic | Semaglutide | 91 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 33 |
| Synthroid | Levothyroxine Sodium | 86 | 19 |
| Bupropion Xl | Bupropion Hcl | 84 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 22 |
| Lorazepam | Lorazepam | 81 | 17 |
| Jardiance | Empagliflozin | 80 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 79 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 13 |
| Montelukast Sodium | Montelukast Sodium | 72 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 70 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 14 |
| Prednisone | Prednisone | 69 | 45 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 14 |
| Valacyclovir | Valacyclovir Hcl | 63 | 19 |
| Temazepam | Temazepam | 62 | 12 |
| Mounjaro | Tirzepatide | 59 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 21 |
| Cefdinir | Cefdinir | 53 | 48 |
| Estradiol | Estradiol | 53 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 12 |
| Celecoxib | Celecoxib | 50 | suppressed |
| Spironolactone | Spironolactone | 49 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 13 |
| Pregabalin | Pregabalin | 46 | 14 |
| Enalapril Maleate | Enalapril Maleate | 44 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | 15 |
| Warfarin Sodium | Warfarin Sodium | 40 | 11 |
| Azithromycin | Azithromycin | 39 | 35 |
| Fluconazole | Fluconazole | 39 | 15 |
| Ondansetron Odt | Ondansetron | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 39 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Gemfibrozil | Gemfibrozil | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 14 |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 11 |
| Pradaxa | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Adapalene | Adapalene | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Procysbi | Cysteamine Bitartrate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $547.73 · 37 records | PFIZER INC. | ABRYSVO, BREZTRI, COMIRNATY, DUPIXENT, ELIQUIS, Kcentra, MOUNJARO, NURTEC ODT, OPSUMIT, OTEZLA, PREVNAR 20, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, QULIPTA, REPATHA, UBRELVY, UPTRAVI, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error